BioRestorative Therapies (BRTX) Q2 2025 earnings summary

Executive summary

• Achieved strong execution across all business areas in Q2 2025, with key clinical milestones including positive Phase II data for BRTX-100 targeting chronic lumbar disc disease.

• Revenue for Q2 2025 was $303,300, up from $89,100 in Q2 2024, driven by BioCosmeceuticals and cosmetic product sales.

• Net loss for Q2 2025 was $2.7 million ($0.30/share), improved from $4 million ($0.50/share) in Q2 2024.

• Advanced two core clinical programs: BRTX-100 for CLDD and ThermoStem for metabolic disorders, with ongoing licensing discussions.

• Research and development expenses rose due to increased clinical trial activity and lab supply costs.

Financial highlights

• Q2 2025 revenue was $303,300, up 240% year-over-year, with gross profit of $294,571.

• Loss from operations was $3.3 million, compared to $2.5 million in Q2 2024.

• Ended Q2 2025 with $7.4 million in cash, cash equivalents, and marketable securities, and no debt.

• Operating expenses for Q2 2025 were $3.6 million, up from $2.55 million in Q2 2024.

• Working capital was $3.93 million as of June 30, 2025.

Outlook and guidance

• Optimistic about continued enrollment and positive trends in BRTX-100 Phase II trial, with plans to present more data and meet with the FDA for regulatory acceleration.

• Management expects continued net losses and negative cash flows as development and clinical activities progress.

• Current funds are insufficient for long-term operations, raising substantial doubt about the ability to continue as a going concern without additional financing.

• Research and development expenses are expected to increase due to ongoing clinical trials.

• SG&A expenses expected to be heavier in Q1 and lighter in subsequent quarters, with potential cooldown in 2026 as enrollment completes.